A Research Agenda for Malaria Eradication: Drugs

English version České info

Antimalarial drugs will be essential tools at all stages of malaria elimination along the path towards eradication, including the early control or “attack” phase to drive down transmission and the later stages of maintaining interruption of transmission, preventing reintroduction of malaria, and eliminating the last residual foci of infection. Drugs will continue to be used to treat acute malaria illness and prevent complications in vulnerable groups, but better drugs are needed for elimination-specific indications such as mass treatment, curing asymptomatic infections, curing relapsing liver stages, and preventing transmission. The ideal malaria eradication drug is a coformulated drug combination suitable for mass administration that can be administered in a single encounter at infrequent intervals and that results in radical cure of all life cycle stages of all five malaria species infecting humans. Short of this optimal goal, highly desirable drugs might have limitations such as targeting only one or two parasite species, the priorities being Plasmodium falciparum and Plasmodium vivax. The malaria research agenda for eradication should include research aimed at developing such drugs and research to develop situation-specific strategies for using both current and future drugs to interrupt malaria transmission.

Vyšlo v časopise: A Research Agenda for Malaria Eradication: Drugs. PLoS Med 8(1): e32767. doi:10.1371/journal.pmed.1000402
Kategorie: Review
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000402

Souhrn

Zdroje

1. ChandaP

HamainzaB

MulengaS

ChalweV

MsiskaC

2009 Early results of integrated malaria control and implications for the management of fever in under-five children at a peripheral health facility: A case study of Chongwe rural health centre in Zambia. Malar J 8 49

2. 2007 United Arab Emirates certified malaria-free. Wkly Epidemiol Rec 82 30 32

3. PloweCV

2009 The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg 103 S11 S14

4. TakalaSL

PloweCV

2009 Genetic diversity and malaria vaccine design, testing and efficacy: Preventing and overcoming ‘vaccine resistant malaria’. Parasite Immunol 31 560 573

5. Kelly-HopeL

RansonH

HemingwayJ

2008 Lessons from the past: managing insecticide resistance in malaria control and eradication programmes. Lancet Infect Dis 8 387 389

6. PloweCV

AlonsoP

HoffmanSL

2009 The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J Infect Dis 200 1646 1649

7. The Roll Back Malaria Partnership 2010 The global malaria action plan for a malaria-free world. Geneva The Roll Back Malaria Partnership

8. PriceRN

TjitraE

GuerraCA

YeungS

WhiteNJ

2007 Vivax malaria: Neglected and not benign. Am J Trop Med Hyg 77 79 87

9. MarshK

1992 Malaria–a neglected disease? Parasitology 104 S53 S69

10. SongJ

SocheatD

TanB

DaraP

DengC

2010 Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J 9 57

11. AlkerAP

LimP

SemR

ShahNK

YiP

2007 Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 76 641 647

12. DondorpAM

NostenF

YiP

DasD

PhyoAP

2009 Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361 455 467

13. NyuntMM

PloweCV

2007 Pharmacologic advances in the global control and treatment of malaria: Combination therapy and resistance. Clin Pharmacol Ther 82 601 605

14. BoniMF

SmithDL

LaxminarayanR

2008 Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci U S A 105 14216 14221

15. PriceRN

DorseyG

AshleyEA

BarnesKI

BairdJK

2007 World Antimalarial Resistance Network (WARN) I: Clinical efficacy of antimalarial therapy. Malar J 6 119

16. Cox-SinghJ

DavisTM

LeeKS

ShamsulSS

MatusopA

2008 Plasmodium knowlesi malaria in humans is widely distributed and potentially life threatening. Clin Infect Dis 46 165 171

17. NajeraJA

2001 Malaria control: Achievements, problems and strategies. Parassitologia 43 1 89

18. FeachemRGA

2010 Shrinking the malaria map: A guide on malaria elimination for policy makers. Chapter 6. San Francisco The Global Health Group, UCSF Global Health Sciences

19. SnowdenFM

2005 The conquest of malaria. Italy 1900-1962. New Haven Yale University Press

20. Bruce-ChwattLJ

1959 Malaria research and eradication in the USSR. A review of Soviet achievements in the field of malariology. Bull World Health Organ 21 737 772

21. KanekoA

TaleoG

KalkoaM

YamarS

KobayakawaT

2000 Malaria eradication on islands. Lancet 356 1560 1564

22. von SeidleinL

GreenwoodBM

2003 Mass administrations of antimalarial drugs. Trends Parasitol 19 452 460

23. MolineauxL

GramicciaG

1980 The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. Geneva World Health Organization

24. HanET

LeeDH

ParkKD

SeokWS

KimYS

2006 Reemerging vivax malaria: Changing patterns of annual incidence and control programs in the Republic of Korea. Korean J Parasitol 44 285 294

25. DolaSK

1974 Mass drug administration as a supplementary attack measure in malaria eradication programme. East Afr Med J 51 529 531

26. PinottiM

1954 A new method of malaria prophylaxis: The addition of an antimalarial drug to cooking salt used in daily preparation of food. Rev Brasil Malariol 6 5 12

27. PetersW

1970 Chemotherapy and drug resistance in malaria. London Academic Press

28. ClydeDF

1965 Duration of antimalarial activity of cycloguanil pamoate amond semi-immune Africans in Tanzania. WHO/MAL/506.65. Geneva World Health Organization

29. NoedlH

SeY

SchaecherK

SmithBL

SocheatD

2008 Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359 2619 2620

30. The malERA Consultative Group on Vaccines 2011 A research agenda for malaria eradication: Vaccines. PLoS Med e1000398 doi:10.1371/journal.pmed.1000398

31. PetersW

1957 A malaria survey in the Western District of Papua. P N G Med J 2 25 38

32. RuwendeC

KhooSC

SnowRW

YatesSN

KwiatkowskiD

1995 Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 376 246 249

33. CorteseJF

CaraballoA

ContrerasCE

PloweCV

2002 Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186 999 1006

34. WhiteNJ

OlliaroPL

1996 Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria. Parasitol Today 12 399 401

35. NyuntMM

HendrixCW

BakshiRP

KumarN

ShapiroTA

2009 Phase I/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites. Am J Trop Med Hyg 80 528 535

36. DondorpAM

YeungS

WhiteL

NguonC

DayNP

2010 Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol 8 272 280

37. The malERA Consultative Group on Modeling 2011 A research agenda for malaria eradication: Modeling. PLoS Med e1000403 doi:10.1371/journal.pmed.1000403

38. The malERA Consultative Group on Health Systems and Operational Research 2011 A research agenda for malaria eradication: Health systems and operational research. PLoS Med e1000397 doi:10.1371/journal.pmed.1000397

39. The malERA Consultative Group on Monitoring, Evaluation, and Surveillance 2011 A research agenda for malaria eradication: Monitoring, evaluation, and surveillance. PLoS Med e1000400 doi:10.1371/journal.pmed.1000400

40. The malERA Consultative Group on Integration Strategies 2011 A research agenda for malaria eradication: Cross-cutting issues for eradication. PLoS Med e1000404 doi:10.1371/journal.pmed.1000404